Cervical Cancer Prevention

Translate to Spanish or other 102 languages!

In Texas, Hispanic women have a higher incidence (15.1 per 100,000 women, compared to 8.1 per 100,000 among white women) and are 1.9 times more likely to die from the disease. Courtesy Image
In Texas, Hispanic women have a higher incidence (15.1 per 100,000 women, compared to 8.1 per 100,000 among white women) and are 1.9 times more likely to die from the disease. Courtesy Image

Mega Doctor News

- Advertisement -

Regular pap tests and HPV testing can prevent and often catch cases of cervical cancer.

Each year, approximately 13,000 women are diagnosed with cervical cancer and about 4,000 women die from cervical cancer in the US. Sixty percent of cervical cancers occur in resource- poor communities.

In Texas, Hispanic women have a higher incidence (15.1 per 100,000 women, compared to 8.1 per 100,000 among white women) and are 1.9 times more likely to die from the disease.

- Advertisement -

Hispanic women residing on the US-Mexico border have even higher cervical cancer incidence rates, a high late-diagnosis rate, and one of the highest mortality rates in the US.

Screening rates among Hispanic women along the border are suboptimal.

Courtesy Image

At Texas Tech University Health Sciences Center El Paso, the De Casa en Casa program is reducing the burden of cervical cancer by facilitating early diagnosis and access to treatment. The program offers educational sessions, no-cost cancer screenings, and diagnostic testing. The program covers 105 West Texas counties, including El Paso and Hudspeth counties.

- Advertisement -
- Advertisement -

- Advertisement -

More Articles

STHS Dedicating Latest “South Texas Healthy Living” Episode to Arthritis Education, July 26th

More than 58 million U.S. adults are living with doctor-diagnosed arthritis, according to the Centers for Disease Control and Prevention (CDC), making it the nation’s leading cause of disability.

No More Needles: FDA Approves First Daily Pill to Replace Injectable Cholesterol Drugs

The U.S. Food and Drug Administration approved Lipfendra (enlicitide), the first oral inhibitor of proprotein convertase subtilisin/kexin type 9 (PCSK9), as an adjunct to diet and exercise to reduce low-density lipoprotein cholesterol (LDL-C), or “bad” cholesterol, in adults with hypercholesterolemia, including those with heterozygous familial hypercholesterolemia (HeFH). Image source: Merck.com.

Physicians Warn of Rising ER Visits Linked to E-Bikes and Scooters

Mega Doctor News CLEVELAND CLINIC - As electric bikes and scooters grow in...

STHS Heart Ranks Among Nation’s Top Hospitals for Heart Attack Care

Every year, more than 800,000 people in the United States suffer a heart attack, according to the Centers for Disease Control and Prevention, an event that occurs approximately every 40 seconds.
- Advertisement -